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Experience-dependent plasticity at excitatory synapses of the mesocorticolimbic system is a fundamental
brain mechanism that enables adaptation to an ever-changing environment. These synaptic responses are
critical for the planning and execution of adaptive behaviors that maximize survival. The mesocorticolimbic
systemmediates procurement of positive reinforcers such as food and sex; however, drugs of abuse resculpt
this crucial circuitry to promote compulsive drug-seeking behavior. This review will discuss the long-term
changes in glutamatergic neurotransmission that occur within the mesolimbic system following cocaine
exposure. In addition, we will examine how these long-lasting neuroadaptations may drive the pathology
of psychostimulant addiction. Finally, we review clinical trials that highlight antagonists at excitatory
AMPA receptors as promising targets against cocaine abuse.Psychostimulant Abuse: An Overview
In the past few decades, psychostimulant addiction has become
increasingly appreciated as a neuropathological disorder
marked by chronic and compulsive relapse episodes during
which the drive to seek and use drugs cannot be controlled
(O’Brien, 1996). This may be due to genetic and socioeconomic
conditions combined with pharmacologically induced effects
that, upon continued drug use, favor the execution of rigid,
drug-associated behaviors in lieu of more adaptive and flexible
responding (Kalivas and Volkow, 2005; Kalivas and O’Brien,
2008; Koob et al., 1998). The persistence of drug-induced alter-
ations in brain function has been hypothesized to exacerbate the
recidivistic and compulsive nature of drug addiction (Hyman
et al., 2006). Thus, addiction is increasingly regarded as an aber-
rant form of learning (Hyman and Malenka, 2001; Jones and
Bonci, 2005). Efforts to understand the molecular basis of this
complex disease must therefore rely upon an integrated under-
standing of how commonly abused drugs alter the synaptic plas-
ticity, neurophysiology, and behavior of model organisms.
Mesocorticolimbic System: General Concepts
The mesocorticolimbic system comprises several intercon-
nected brain regions, including the ventral tegmental area
(VTA) and substantia nigra, dorsal striatum, ventral striatum
(nucleus accumbens, NAcb), and the amygdala, as well as the
frontal cortical regions that correspond to rat prefrontal cortex
or human anterior cingulate (Goldstein and Volkow, 2002; Ongu¨r
and Price, 2000). The VTA, NAcb, and frontal cortex comprise an
integral part of the motivational circuit (Figure 1) (Mogenson
et al., 1993). The major source of dopamine (DA) to forebrain
structures, such as the prefrontal cortex and NAcb, arisesfrom cell bodies in the VTA of the midbrain (Fields et al., 2007).
The important and complex role of DA in motivated behavior
and learning has been previously reviewed (Berke and Hyman,
2000; El-Ghundi et al., 2007; Nicola et al., 2000), and previous
work supports the hypothesis that the NAcb, a primary target
of the VTA, serves as a limbic-motor interface that pro-
cesses reward valence and modulates motivational drives in
order to execute both novel and more habitual responding
(Kelley, 2004; Koob and Le Moal, 2001; Mogenson et al., 1993;
Nestler, 2005; Nicola et al., 2000; Pierce and Kumaresan,
2006; Smith, 2004). The NAcb has two main regions, with the
NAcb core important for control of motivated behavior by condi-
tioned cues and the NAcb shell most often implicated in pro-
cessing of primary reward and novelty.
Increased extracellular DA concentrations, such as that
elicited by abused drugs, facilitate learning (Jay, 2003; Kelley,
2004), including relationships between the behavioral response
to drug-related stimuli and drug-mediated reinforcement (Berke
and Hyman, 2000; Nestler, 2001). For example, dorsal striatal DA
release from the nigrostriatal pathway is necessary for habit
learning (Faure et al., 2005), and repeated amphetamine expo-
sure, which enhances DA levels, augments subsequent habit
formation (Nelson and Killcross, 2006). Moreover, in addition to
shaping learning about drug reinforcement, DA may also modu-
late the motivation to seek drugs independent from their
perceived hedonic value (Berridge and Robinson, 1998). Intrigu-
ingly, upon repeated pairing of a natural reinforcer like sucrose
and a cue that predicts that reinforcer, midbrain DA neurons
no longer exhibit phasic firing for the reinforcer and only fire for
the predictive cue (Schultz, 1998, 2004). Thus, DA neuronalNeuron 67, July 15, 2010 ª2010 Elsevier Inc. 11
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Figure 1. Motivational Circuit
The major reward centers implicated in drug
addiction. Dopaminergic projections from the
ventral tegmental area (VTA) provide the major
source of dopamine to prefrontal cortex (PFC)
and nucleus accumbens (NAcb).
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fulfill predicted valence expectations, which is hypothesized to
facilitate adaptive responding (Schultz, 2004). In contrast, DA
release following presentation of drug rewards and drug-associ-
ated cues persists (Ito et al., 2002; Kalivas and O’Brien, 2008;
Volkow et al., 2006).
Increased DA release with repeated drug exposure supports
theories suggesting that drugs of abuse modify normally adap-
tive circuitry to be more responsive to drug stimuli and thus
less flexible (Berridge and Robinson, 1998; Everitt and Robbins,
2005; Goldstein and Volkow, 2002; Kalivas, 2008). Drug-seeking
behavior following repeated drug use is thought to be driven by
a persistent, maladaptive allostatic state (Koob and Le Moal,
1997) and/or by altered attribution of incentive salience (Berridge
and Robinson, 1998) rather than by drug-associated positive
reinforcement. Additional work is required to determine how
these addiction model interpretations map onto humans, and
congruence across species remains a largely unaddressed,
but increasingly recognized, chasm between clinical and preclin-
ical data sets. The molecular mechanisms central to rodent
synaptic plasticity following psychostimulant exposure high-
lighted in this review may also be predictive of clinically relevant
and pharmacologically tractable targets for treatment of human
psychostimulant addiction.
While much of the addiction literature has focused on the
dopaminergic system, other neurotransmitter systems are rele-
vant to psychostimulant-induced plasticity and pharmacolog-
ical and pharmacogenetic interventions for addiction has
been addressed, including important distinctions between glu-
tamatergic response of the mesocorticolimbic system to
repeated cocaine or amphetamine exposure (Cobos et al.,
2008; Haile et al., 2009; Kalivas and O’Brien, 2008; Knackstedt
et al., 2010; Wolf, 1998; Xi and Gardner, 2008; Yahyavi-Firouz-
Abadi and See, 2009). This review will focus on drug-related
changes in the glutamatergic system. Thus, there is an anatom-
ical basis for a close association between dopaminergic and
glutamatergic molecular plasticity due to the synaptic triad
ultrastructure, where DA and glutamate afferents converge on
the same neuron, with DA receptors preferentially on the neck
of the spine and glutamate receptors on the spine head (Sesack
et al., 2003). Thus, ascending dopaminergic input can shape12 Neuron 67, July 15, 2010 ª2010 Elsevier Inc.synaptic integration of cortical and allo-
cortical glutamatergic afferents.
Operant Models of Psychostimulant
Abuse: The Role of Glutamate
Animal models of drug addiction, specifi-
cally operant self-administration (Davis
and Smith, 1976; de Wit and Stewart,
1981), facilitate a mechanistic dissection
of the neurophysiology and molecularplasticity that could support human drug addiction. In such
experiments, laboratory rodents and nonhuman primates are
trained to manipulate an operandum, such as a lever or nose-
poke, which delivers a reinforcer in a contingent fashion. This
method of operant, drug self-administration has been utilized
for nearly all drugs abused by humans. Importantly, these models
involve voluntary drug intake, in contrast to other commonly used
models where animals experience passive drug exposure.
Operant models of self-administration can be extended to
study the mechanisms thought to underlie craving and relapse
by establishing a prolonged drug-free period after self-adminis-
tration sessions (forced abstinence) or by initiating extinction
training. During extinction, operant responding no longer
delivers drug, thus responding significantly declines (Davis and
Smith, 1976). After forced abstinence or extinction, an animal
can be exposed to stimuli to precipitate drug-seeking behavior
(‘‘relapse’’). Such stimuli include situations that approximate
stressful events, cues predictive of drug reinforcement, or drug
re-exposure. A number of studies have suggested that these
models of drug relapse are useful for pharmacotherapeutic
screening (Epstein et al., 2006).
This review will refer to studies employing either operant or
passive drug-exposure models to probe AMPAR-mediated plas-
ticity. Importantly, the extinction-reinstatement model has been
used to demonstrate a central role of NAcb AMPAR (Cornish
et al., 1999; Cornish and Kalivas, 2000; Di Ciano and Everitt,
2001; McFarland and Kalivas, 2001; McFarland et al., 2004) and
glutamate released from prefrontal afferents into the NAcb
(McFarland et al., 2003; Park et al., 2002) for cue-primed
(Ba¨ckstro¨m and Hyytia¨, 2007; Di Ciano and Everitt, 2001), stress-
primed (McFarland et al., 2004), and cocaine-primed (Bachtell
et al., 2008; Cornish and Kalivas, 2000; Ping et al., 2008) reinstate-
ment. In general, striatal AMPAR antagonism prevents relapse
while AMPAR activation promotes it (Cornish et al., 1999; Cornish
and Kalivas, 2000; Di Ciano and Everitt, 2001; McFarland et al.,
2004; Suto et al., 2004; Vanderschuren et al., 2005), but this may
be an oversimplified hypothesis (Bachtell et al., 2008).
There is general agreement that the glutamatergic projection
from the prefrontal cortex to the NAcb core is critical for the
reinstatement of cocaine-seeking behavior (Bachtell et al.,
2008; Ba¨ckstro¨m and Hyytia¨, 2007; Cornish et al., 1999; Cornish
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Figure 2. AMPA Receptor Plasticity
(A) Tetrameric AMPA receptors in control (top) and
potentiated (bottom) state. In control conditions,
AMPA receptors typically contain the GluA2
subunit. Following cocaine exposure (either non-
contingently or through self-administration), there
is an increase in GluA2-lacking AMPA receptors.
GluA2-lacking AMPARs have greater channel
conductance and are permeable to Ca2+.
(B) Changes in AMPAR subunit composition
during naive, early withdrawal, and late withdrawal
stages of cocaine addiction in the NAcb (top) and
VTA (bottom). AMPAR subunit composition is
altered at each of these three stages of cocaine
addiction.
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2003, 2004; Park et al., 2002; Ping et al., 2008). Importantly,
upon repeated performance, drug-seeking behavior becomes
less adaptive and less receptive to shaping via anterior cingulate,
prefrontal, and orbital frontal executive oversight (Everitt and
Robbins, 2005; Goldstein and Volkow, 2002; Kalivas, 2008;
Kalivas and Volkow, 2005), with greater control exerted by
sensory-motor cortical input into the dorsal striatum (Everitt
and Robbins, 2005). Importantly, recent evidence also suggests
that the ventral and dorsal striatum interact to control habitual
behavior (Belin and Everitt, 2008). Together, these data suggest
that repeated psychostimulant use reduces cortical interaction
with habit circuitry. However, during drug abstinence, relapse
can be precipitated by increased cortical activity that may feed
forward into what now may be habitual, drug-directed responses.
It is important to recognize both the strengths and possible
limitations of the animal models used to investigate the neural
mechanisms of drug relapse. Recent work has addressed the
brain circuits important for relapse in rodents after forced absti-
nence without extinction training. These studies have shown
a critical role for the dorsal striatum and midbrain, but not
a number of other mesocorticolimbic structures that mediate
reinstatement after extinction (Fuchs et al., 2006; See et al.,
2007). Extinction experiments in rodents appear to more closely
parallel imaging data generated from human psychostimulant
addicts (Fuchs et al., 2006; Kalivas, 2008; Kalivas and O’Brien,
2008; Shalev et al., 2002), and extinction efforts have yielded
some clinical success (O’Brien et al., 1992). Thus, while these
data may be particularly relevant to human addiction, additional
temporary inactivation experiments with the abstinence model
and more complex choice and devaluation paradigms are
needed to provide more thorough insight into human addiction.
Psychostimulant-Induced Synaptic Plasticity
Rapid, excitatory neuronal transmission is primarily mediated
through the activation of ionotropic glutamate receptors. Iono-Neurotropic glutamate receptors are present in
two distinct classes: alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic
acid receptors (AMPARs) and N-methyl-
D-aspartate receptors (NMDARs). AM-
PARs are typically composed of four
subunit proteins (GluA1-A4), which canform hetero or homomeric complexes. Under basal conditions,
the tetrameric AMPAR is often composed of GluA2 subunits in
complex with either GluA1 or GluA3 (Dingledine et al., 1999)
(Figure 2A).
Increased AMPAR function is observed after exposure to psy-
chostimulants, which can significantly modulate reward-
directed behavior. Synapses can be strengthened or weakened
in response to changing neuronal activity, a mechanism that is
thought to underlie learning and memory. Following induction
of long-term potentiation (LTP), synaptic strengthening can be
achieved through active insertion of GluA2-lacking AMPARs
(i.e., GluA1/A1 or GluA1A/3 receptors). Compared with GluA2-
containing AMPARs, GluA2-lacking AMPARs have greater
channel conductance, are calcium permeable, and can there-
fore trigger calcium-dependent signaling cascades (Figure 2A)
(Kauer and Malenka, 2007). Conversely, long-term depression
(LTD) is associated with removal of AMPARs from synapses
(Malinow and Malenka, 2002); thus, AMPAR trafficking is
a powerful and rapid mechanism by which synapses can be
strengthened and weakened to affect behavior. Furthermore,
changes in phosphorylation state or splice variants can also
regulate AMPAR-mediated synaptic transmission (Braithwaite
et al., 2000; Kessels and Malinow, 2009; Wang et al., 2005).
In general, GluA1 phosphorylation increases AMPAR currents
(Derkach et al., 1999; Roche et al., 1996) and can also drive
insertion of AMPARs into synapses (Esteban et al., 2003), which
can strengthen synapses and lead to LTP.
Cocaine-Induced Synaptic Plasticity: VTA
Phasic VTA DA neuron activity is induced by reward-predictive
cues (Schultz, 1998), implicating a critical role for DA neurons
in responding to positive reinforcement. This transition from
a tonic spike firing mode to phasic firing can be modulated by
glutamatergic afferents onto DA neurons (Mathon et al., 2003;
White, 1996). Thus, alterations in glutamatergic input onto VTA
DA neurons could significantly alter DA release in terminal
regions. Glutamatergic synapses onto VTA DA neurons andn 67, July 15, 2010 ª2010 Elsevier Inc. 13
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LTP and LTD of evoked AMPAR-mediated synaptic responses
(Bellone and Lu¨scher, 2005; Bonci and Malenka, 1999; Robbe
et al., 2002). Interestingly, following reward-related learning, an
NMDA-dependent potentiation of AMPAR-mediated synaptic
response of VTA DA neurons is observed (Stuber et al., 2008).
Since drug exposure can also enhance AMPAR function in the
VTA, these data collectively support the hypothesis that drugs
of abuse can co-opt brain circuitry that processes motivationally
relevant non-drug stimuli.
Potentiation of AMPAR-mediated responses in VTA DA
neurons is observed 24 hr following single or multiple noncontin-
gent cocaine injection (Argilli et al., 2008; Borgland et al., 2004;
Ungless et al., 2001). Cocaine-induced AMPAR potentiation is
mediated through enhanced trafficking of GluA2-lacking AMPA
receptors into the synapse (Figure 2B; Argilli et al., 2008; Bellone
and Lu¨scher, 2006). In addition, this increase in synaptic AM-
PARs is indicative of synapses in a potentiated state, which
can prevent further synaptic plasticity (Argilli et al., 2008). Impor-
tantly, activation of mGlu1 reverses cocaine-induced potentia-
tion through the exchange of GluA2-lacking AMPARs with
GluA2-containing AMPARs (Bellone and Lu¨scher, 2006; Mameli
et al., 2007), restoring these synapses back to their pre-drug
states.
Potentiation of AMPAR function is not limited to cocaine, as
noncontingent injections of nicotine, alcohol, amphetamine, or
morphine can also elicit a LTP-like potentiation of glutamate
transmission onto VTA DA neurons (Saal et al., 2003). Thus, glu-
tamatergic synapses onto VTA DA neurons are equally
enhanced following reward-related learning and after exposure
to drugs of abuse; however, the potentiation of glutamatergic
input onto VTA DA neurons is transient. Following non-drug
reward-related learning, synaptic potentiation persists for 2 to
7 days depending on the behavioral task (Chen et al., 2008;
Stuber et al., 2008), but is absent by 14 days after the last
reward-learning training session (Chen et al., 2008). Similarly,
a short-lasting potentiation is also observed following a single
intraperitoneal (i.p.) cocaine injection, with enhanced AMPAR
function evident after 1 and 5 but not 10 days of abstinence
(Ungless et al., 2001). Because relapse to cocaine-seeking
behavior can occur even after a prolonged period of abstinence,
one wonders whether repeated cocaine exposures would
induce a longer-lasting potentiation of VTA DA neurons. Surpris-
ingly, even when rats were administered noncontingent cocaine
injections across for 7 consecutive days (Borgland et al., 2004),
the duration of LTP onto VTA DA neurons was not increased and
returned to baseline levels after 10 days of abstinence. Thus,
despite repeated cocaine exposure, the short-lived potentiation
of glutamatergic synapses suggests that cocaine-induced
synaptic changes in VTA DA neurons represent a transient neu-
roadaptation to cocaine exposure.
In sharp contrast to the effect of noncontingent cocaine injec-
tions, voluntary cocaine self-administration induced LTP at VTA
DA neurons that persisted for up to 3 months of abstinence
(Chen et al., 2008). This did not reflect the pharmacological
effects of cocaine, as repeated administration of noncontingent
i.v. cocaine in a similar pattern and concentration resulted in only
a short-lasting potentiation of AMPAR function. These results14 Neuron 67, July 15, 2010 ª2010 Elsevier Inc.suggest that the voluntary intake of cocaine plays a critical role
in the long-lasting potentiation of AMPAR function on VTA DA
neurons that extends beyond the primary mechanism of drug
action itself. We speculate that the requirement for voluntary
intake may reflect the contribution of an active learning mecha-
nism, so that persistent AMPAR potentiation only develops
when the animal undergoes learning in relation to the voluntary
intake of cocaine. Furthermore, LTP at VTA DA neurons induced
by voluntary cocaine self-administration remained potentiated
even after drug-seeking behavior was extinguished, and AMPAR
function was not further enhanced following cue-induced rein-
statement (Chen et al., 2008). Together these data suggest
that glutamate function at VTA DA neurons is maximally potenti-
ated following cocaine self-administration; more importantly,
this potentiation is unchanged even after cocaine-seeking
behavior is extinguished. The intractability of cocaine-induced
potentiation at DA neurons is in sharp contrast to plasticity
induced by natural-reward learning. For example, extinction of
behaviors associated with natural-reward learning also reverses
the synaptic potentiation induced during the initial acquisition of
these tasks (Pan et al., 2008). This suggests that glutamate
synapses onto VTA DA neurons are capable of expressing bidi-
rectional plasticity to support both learning and unlearning. Thus,
the persistent potentiation at VTA DA neuron synapses following
cocaine self-administration may be instrumental in the mainte-
nance of a drug ‘‘memory’’ despite years of abstinence that
may facilitate the reinstatement of drug-seeking behaviors
(Nestler, 2001).
In summary, the pharmacological effect of cocaine and other
drugs of abuse induce a transient potentiation of glutamatergic
projections onto VTA DA neurons. Importantly, synaptic neuroa-
daptations induced through voluntary cocaine self-administra-
tion sessions are persistent, and remain potentiated despite
extinction of cocaine-seeking behavior. Several important ques-
tions remain unanswered. Numerous brain regions are activated
by drugs of abuse (Pierce and Kumaresan, 2006), many of which
provide extensive excitatory projections onto VTA DA neurons
(Colussi-Mas et al., 2007; Fields et al., 2007; Geisler et al.,
2008). Traditional ex vivo electrophysiology techniques lack
the precision to isolate region-specific afferents synapsing
onto VTA DA neurons. Fortunately, with the development of op-
togenic approaches (Zhang et al., 2007), it is now possible to
identify region-specific glutamatergic projections that may be
differentially modulated by cocaine and other drugs of abuse.
In addition, in vivo electrophysiological techniques (Lee et al.,
2006) offer another promising tool in which drug-induced alter-
ations in synaptic function can be examined in the intact animal.
This technique will be especially useful to study drug-mediated
changes in synaptic function between interconnected brain
regions, which is not possible using classic slice electrophysi-
ology. Development and implementation of these new technolo-
gies by addiction researchers will greatly aid our understanding
of the neurophysiological consequences of drug abuse.
Cocaine-Induced Synaptic Plasticity: NAcb
NAcb AMPAR activation is implicated in many cocaine-seeking
behaviors (Conrad et al., 2008; Cornish and Kalivas, 2000;
Di Ciano and Everitt, 2001; Ping et al., 2008; Suto et al., 2004).
In addition, a number of studies have suggested that NAcb
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cocaine self-administration (Conrad et al., 2008; Famous et al.,
2008) and during abstinence following repeated passive expo-
sure to cocaine (Kourrich et al., 2007; Thomas et al., 2001).
Thus, there is considerable interest in understanding the molec-
ular basis for changes in NAcb AMPAR function, since this could
facilitate the development of novel pharmacotherapies for psy-
chostimulant addiction.
Passive cocaine exposure can alter NAcb AMPAR function,
but on a different time course than in the VTA. While potentiation
of AMPAR-mediated activity in VTA DA neurons was observed
as early as 3 hr after a single cocaine exposure (Argilli et al.,
2008); modulation of NAcb AMPAR function was unaffected by
a single cocaine injection. Instead, changes in Nacb glutamate
function occur only following repeated cocaine injections
(Kourrich et al., 2007; Thomas et al., 2001). In sharp contrast to
the VTA, alterations in glutamatergic transmission in the NAcb
exhibited a biphasic effect. Ex vivo electrophysiological analysis
reveals depressed AMPAR function in the shell but not the core
of the NAcb in early withdrawal from repeated non-contingent
cocaine injections (24 hr after last exposure) (Kourrich et al.,
2007), consistent with a decreased AMPAR-mediated response
of NAcb neurons observed in vivo (White et al., 1995) and in
biochemical experiments (Boudreau et al., 2007). However, after
a longer abstinence period (>10 days), AMPAR function is
enhanced (Boudreau et al., 2007; Kourrich et al., 2007). Interest-
ingly, re-exposure to cocaine during abstinence reverses the
potentiated AMPAR function to a decreased AMPAR function
(Kourrich et al., 2007). This rapid, cocaine-induced reversal in
AMPAR function is mirrored by a decrease in AMPAR surface
expression (Boudreau et al., 2007) and decreased efficacy of
intra-NAcb AMPAR to modulate locomotion (Bachtell et al.,
2008) following cocaine exposure. In addition, repeated amphet-
amine administration did not alter GluA1 or GluR2 surface
expression in the NAcb (Nelson and Killcross, 2006), but did up-
regulate the flip isoform of GluA2 (Yu et al., 2005), which can
dramatically alter fast channel kinetics (Mosbacher et al., 1994).
Unlike the effects of noncontingent infusions of cocaine, the
effects of voluntary cocaine self-administration on glutamatergic
function in the NAcb are generally similar to that observed in the
VTA. One difference from the VTA is that self-administration of
cocaine also elicits a biphasic response in AMPAR function
during abstinence. In early abstinence, a depression of AMPAR
function was observed in NAcb shell (Schramm-Sapyta et al.,
2006), but after a longer period of abstinence, an increase in AM-
PAR-mediated response was observed in both the shell
(Anderson et al., 2008) and the core (Conrad et al., 2008). In these
studies, enhanced AMPA function was attributed to a shift in
AMPAR subunit composition, leading to greater channel
conductance. Anderson et al. (2008) observed an increase in
cell-surface expression of GluA1-containing AMPARs, while
Conrad et al. (2008) saw an increase in GluA2-lacking AMPARs
(Conrad et al., 2008). The increase in GluA2-lacking AMPAR
appears to play an important role in facilitating the incubation
of cocaine craving (Figure 2B; Conrad et al., 2008), and
promoting GluA2 surface expression in either the NAcb core or
shell attenuated the capacity of cocaine to reinstate extin-
guished drug-seeking behavior (Famous et al., 2008). Moreover,GluA1 and GluA2 trafficking increased during the extinction of
cocaine-seeking behavior (Ghasemzadeh et al., 2009), and the
extent of extinction was correlated with the upregulation of
GluA1 (Sutton et al., 2003).
Cocaine self-administration can also alter regulation of gluta-
mate release in the NAcb. Decreased basal extracellular gluta-
mate concentration is observed in the NAcb in animals abstinent
from cocaine self-administration (Baker et al., 2003; Kalivas and
Hu, 2006; Pierce et al., 1996) due to impaired function of the glial
cysteine-glutamate exchanger, which transports glial glutamate
into the extracellular space. The amelioration of this deficit may,
in part, explain the efficacy of glutamate transport modulators to
decrease cocaine seeking (Knackstedt et al., 2010; Baker et al.,
2003; Martı´nez-Raga et al., 2008). Decreased basal glutamate
levels impair the ability for synapses to undergo LTP and/or
LTD in glutamatergic transmission, and indeed, NAcb core
neurons failed to express LTD or LTP in animals withdrawn or
extinguished from voluntary cocaine self-administration, respec-
tively (Martin et al., 2006; Moussawi et al., 2009).
Thus, protracted abstinence from cocaine self-administration
can induce at least two separate alterations in glutamatergic
function in the NAcb. As the period of abstinence proceeds, AM-
PAR-mediated responses are potentiated due to an increase in
synaptic GluA2-lacking AMPARs. These GluA2-lacking AMPARs
in the NAcb may be critical for the enduring drive to seek
cocaine. The second effect of cocaine is its ability to alter the
induction of synaptic plasticity. The persistent neuroadaptations
that occur during abstinence from cocaine self-administration
(Martin et al., 2006; Moussawi et al., 2009), especially the inability
to produce further plastic changes, are an intriguing parallel to
the inflexible responding of individuals repeatedly exposed to
psychostimulants. Thus, AMPAR-selective pharmacotherapeu-
tics could reduce the recidivistic and compulsive nature of
cocaine and amphetamine addiction.
A recent study shows that cocaine-induced potentiation of
glutamatergic transmission in the NAcb requires persistent
VTA potentiation (Mameli et al., 2009). Reversal of cocaine-
induced potentiation in the VTA through activation of mGlu1
prevents enhanced glutamate function in the NAcb and attenu-
ates reinstatement of cocaine-seeking behaviors. While the
mechanism linking the VTA and NAcb is unclear, this study
establishes a clear serial effect of cocaine on glutamate function
in the VTA and NAcb. Thus, voluntary cocaine self-administra-
tion induces a long-lasting potentiation of glutamate function in
the VTA and the NAcb and this persistent synaptic potentiation
may be critical in the continued expression of drug craving.
Moreover, inasmuch as dopamine signaling originating within
the VTA plays an important role in signaling saliency about the
environment (Schultz, 1998), the long-lasting potentiation onto
VTA DA neurons following cocaine self-administration could
act to selectively accentuate drug-related cues while de-empha-
sizing all other non-drug stimuli or cues. This is hypothesized to
bias the animal’s behavior toward drug-related stimuli while
precluding expression of other behaviors. In essence, behavior
flexibility is lost as the animal becomes increasingly focused
on performing drug-associated behaviors (Kalivas and O’Brien,
2008). In the NAcb, similar drug-induced changes in these
neurons can facilitate a preferential excitation of neurons thatNeuron 67, July 15, 2010 ª2010 Elsevier Inc. 15
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execution of drug-associated behaviors.
Second Messenger Pathways that Can Modulate
AMPAR Function
A number of studies has shown that signaling through the cAMP
response element binding protein (CREB)-mediated pathway is
utilized by various forms of reinforcing stimuli, including drugs
of abuse (Carlezon et al., 1998; Nestler, 2001) and non-drug
stimuli (Jin et al., 2005). Both cocaine and amphetamine can acti-
vate the CREB transcriptional machinery via increased CREB
phosphorylation (Carlezon et al., 2005), leading to altered
expression patterns of several transcription factors downstream
of CREB, such as c-fos, zif268, and fosB (Harlan and Garcia,
1998; McGinty et al., 2008), and altered mRNA splicing of Fos
family members that enable accumulation of DFosB (McClung
et al., 2004). Here, we will review CREB-related signaling mech-
anisms that can interface with AMPA receptor plasticity and
perhaps modulate responding for drugs of abuse.
Increased CREB phosphorylation appears to regulate cocaine
reinforcement, as NAcb CREB overexpression reduced the rein-
forcing properties of cocaine while also increasing aversion to
low cocaine doses (Carlezon et al., 1998). Conversely, NAcb
CREB dominant-negative overexpression increased apparent
cocaine-mediated reinforcement (Carlezon et al., 1998).
However, CREB knockdown reduced the reinforcing efficacy
of cocaine when measured via contingent cocaine delivery after
instrumental responding (Choi et al., 2006) rather than if
measured via Pavlovian conditioning following noncontingent
cocaine exposure (Carlezon et al., 1998). While these data are
themselves very intriguing, the diverse signaling pathways that
impinge onto CREB (Shaywitz and Greenberg, 1999) are
perhaps of even greater interest because phosphorylated
CREB can promote the expression of transcription factors and
other gene products that have also been implicated in addiction,
e.g., preprodynorphin, NAC-1, and the various Homer isoforms
(Hurd and Herkenham, 1993; Nestler, 2001). Thus, CREB may
represent a molecular integrator of second messenger signaling
systems that are common substrates of abused drugs.
Another downstream CREB target, DFosB, is also quite inter-
esting, in part due to a unique, accumulating expression pattern
in DA terminal fields of the mesocorticolimbic circuit following
repeated administration of commonly abused drugs, including
cocaine and amphetamine, as well as following repeated, non-
drug reinforcement (McClung et al., 2004; McClung and Nestler,
2003). DFosB is a transcription factor that acts to upregulate
GluA2 in the NAcb (Kelz et al., 1999) and cyclin-dependent
kinase 5 (Cdk5) in the striatal complex (Bibb et al., 2001) and
hippocampus (Chen et al., 2000). Overexpression of GluA2 in
the NAcb shell decreases intracranial self-stimulation thresholds
(Todtenkopf et al., 2006), suggesting that DFosB accumulation
might augment drug-mediated reinforcement. It has been shown
that DFosB overexpression increases the incentive motivation to
seek both drug and non-drug reinforcement, while DFosB domi-
nant-negative overexpression reduces motivation to seek these
reinforcers (Colby et al., 2003; Nestler, 2005).
Analysis of postmortem midbrain (Tang et al., 2003) and NAcb
(Hemby et al., 2005) tissue collected from human cocaine-over-16 Neuron 67, July 15, 2010 ª2010 Elsevier Inc.dose victims has revealed significant upregulation of CREB and
GluA2. While DFosB accumulation may reflect an important
mechanism contributing to the transition from drug use to drug
abuse (Nestler, 2001), the extent of postmortemDFosB accumu-
lation in human cocaine addicts has not been determined. Addi-
tionally, given that the majority of studies observing increased
AMPAR function after drug exposure have found a decrease
rather than an increase in GluA2 function, the functional rele-
vance of these CREB and Fos family-mediated GluA2 AMPA
subunit changes remains to be fully elucidated. Finally, though
intriguing parallels can be drawn between identified roles of
CREB,DFosB, and AMPA receptor subunits in addiction-associ-
ated behaviors, it has not yet been determined if CREB, DFosB,
and AMPARs lie within the same molecular network.
Psychostimulants can also interact with AMPAR plasticity in
more complex ways. The capacity of DFosB to modulate
AMPA subunit expression is limited by a negative feedback
loop involving inhibition of PKA by Cdk5 and phospho-Thr75
DARPP-32 via DFosB. The DARPP-32 phospho-Tyr75 form is
the predominant form of DARPP-32 following repeated cocaine
exposure (Scheggi et al., 2007). AMPAR activation leads to
dephosphorylation of phospho-Thr75 of DARPP-32 thereby
disinhibiting PKA (Nishi et al., 2002). Thus, the capacity ofDFosB
to limit PKA signaling can be counteracted by increased AMPAR
recruitment (Juo et al., 2007; Kelz et al., 1999; Olson et al., 2005)
In accord with possible AMPAR-mediated PKA disinhibition,
Cdk5 inhibitors augment behavioral sensitization (Bibb et al.,
2001). Thus, DFosB upregulation appears in part homeostatic
(Winstanley et al., 2009), perhaps through a Cdk5-mediated inhi-
bition of PKA, since the DFosB downstream target Cdk5 can
interface with AMPAR and DARPP-32 to modulate psychostimu-
lant reinforcement, motivation, and sensitization.
Although CREB is predominantly thought of in relation to PKA-
mediated signaling, extracellular signal-regulated kinase (ERK)
preferentially activates CREB following repeated exposure to
cocaine (Lu et al., 2005). ERK can act directly on AMPARs to
increase AMPAR surface insertion, which is required for expres-
sion of NMDA-dependent LTP (Zhu et al., 2002). Furthermore,
cocaine-induced striatal ERK activation is PKA- and DARPP-
32-dependent, and ERK inhibition attenuated cocaine-induced
conditioned place preference and behavioral sensitization
(Valjent et al., 2005). Moreover, ERK in the central amygdala
was shown to be both necessary and sufficient for the incubation
of cocaine craving (Lu et al., 2005). While ERK acting directly on
AMPA or through DFosB could facilitate the AMPAR role in psy-
chostimulant reinforcement, further work is needed to define the
relationship between ERK and AMPARs, and this remains an
interesting area of investigation.
Synaptic strengthening can be accompanied by neurite
outgrowth, spine splitting, and synaptogenesis. Repeated psy-
chostimulant exposure leads to synaptogenesis in several mes-
ocorticolimbic areas (Li et al., 2004; Pulipparacharuvil et al.,
2008; Robinson and Kolb, 1999; Shen et al., 2009) and several
molecules have been associated with this process, including
the neuronal-activity-regulated pentraxin (Narp). Narp is
secreted into the extracellular matrix, concentrates at excitatory
complexes, and facilitates AMPAR clustering by forming extra-
cellular, multimeric complexes (O’Brien et al., 1999). Following
Neuron
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in the dorsal striatum, hippocampus, and some regions of the
neocortex (Ujike et al., 2002), although a parallel increase in
protein expression was not detectable after either acute or
repeated psychostimulant exposure (Lu et al., 2002). However,
Narp protein expression in the prefrontal cortex was correlated
with the magnitude of spontaneous motoric response to a novel
environment (Lu et al., 2002), and heightened reactivity to novel
situations has been used as a measure of impulsivity and a puta-
tive drug abuse liability indicator (Lu et al., 2002; Stoffel and
Cunningham, 2008). Narp knockout decreased cocaine-medi-
ated reinforcement and time spent in the center of an open field
(Pacchioni et al., 2009). Thus, psychostimulant-induced changes
in Narp can augment AMPAR function and individuals with
higher Narp may also exhibit higher drug abuse liability.
There are several molecular changes that emerge during
abstinence from psychostimulant exposure that are not
apparent in drug-naive animals or after recent drug exposure
(Kalivas and O’Brien, 2008; Lu et al., 2004b). Some of these
enduring molecular events, such as the increased AMPAR func-
tion, are hypothesized to drive the motivation to seek drug during
relapse (Grimm et al., 2001; Kalivas, 2009; Nestler, 2001). In
particular, mRNA for the brain-derived neurotrophic factor
(BDNF) increases across abstinence in brain structures such
as the NAcb and VTA (Filip et al., 2006; Grimm et al., 2003) and
both BDNF and the related glial cell line-derived neurotrophic
factor (GDNF) could support the increased motivation for drugs
that develops across abstinence (Grimm et al., 2003; Lu et al.,
2009). For example, GDNF (Li and Keifer, 2009) and BDNF
(Berglind et al., 2007; Graham et al., 2007; Horger et al., 1999;
Lu et al., 2004a) can reversibly modulate behavior and synaptic
plasticity (Pu et al., 2006) associated with relapse to cocaine-
seeking behavior. However, the effects of growth factors may
differ among brain regions, since BDNF in the prefrontal cortex
can decrease drug seeking (McGinty et al., 2009). Although the
precise mechanisms through which BDNF and GDNF modulate
drug seeking remain unclear, altered AMPAR signaling is an
interesting possibility. For example, LTP induction is facilitated
by an AMPAR-mediated increase in BDNF release and signaling
at excitatory synapses (Jourdi et al., 2009; Lauterborn et al.,
2009), and, conversely, BDNF can enhance LTP induction (Barco
et al., 2005; Pu et al., 2006). BDNF signaling through the
mammalian target of rapamycin (mTor) can increase dendritic
mRNA translation, which, along with LTP, facilitates memory
formation (Jourdi et al., 2009; Lauterborn et al., 2009; Slipczuk
et al., 2009). Moreover, BDNF signals through ERK to increase
AMPAR GluA1 subunit synaptic delivery (Li and Keifer, 2009).
Thus, growth factors such as BDNF and GDNF have multiple
pathways through which they can enhance AMPAR function,
facilitate memory formation, and in this way stabilize memories
that drive drug seeking even after prolonged abstinence from
drugs.
AMPAR Pharmacotherapies: Past, Present, and Future
The translation of the current knowledge about the role of
AMPARs in modulating synaptic plasticity to abate substance
abuse would ideally produce a drug that limits AMPAR activation
and reverses the long-term plasticity associated with continuedcocaine seeking. This strategy is supported by the large body of
rodent literature showing that AMPA antagonists inhibit the rein-
statement of drug-, cue-, or stress-primed drug-seeking
behavior (Ba¨ckstro¨m and Hyytia¨, 2007; Cornish et al., 1999;
Cornish and Kalivas, 2000; Di Ciano and Everitt, 2001;
McFarland and Kalivas, 2001; McFarland et al., 2003, 2004;
Park et al., 2002; Ping et al., 2008; but see Bachtell et al.,
2008). As a consequence, the motivation to self-administer
drug as well as the propensity to relapse would be reduced.
However, given the complexity of the mammalian nervous
system, this may require reagents with broad-spectrum activity
and indeed, several nonspecific glutamatergic agents have
shown much promise (Table 1).
Selective AMPAR Antagonists
In general, AMPAR antagonists compete with glutamate to
prevent AMPAR activation while noncompetitive allosteric
ligands modulate AMPAR activity at a site distinct from the gluta-
mate binding region. Several, structurally distinct classes of
AMPA antagonists have been described including the quinoxali-
nediones, isatin oximes, decahydroisoquinolines and isoxazole
derivatives (Chimirri et al., 1998; Nikam et al., 1999; Nikam and
Kornberg, 2001; So´lyom and Tarnawa, 2002). Historically, these
compounds were developed for indications other than
substance abuse, but the clinical availability of these
compounds provides an exciting opportunity for the treatment
of drug addiction.
The first noncompetitive AMPA antagonist GYKI 52466
(Donevan and Rogawski, 1993) was found among a 2,3-benzo-
diazepine library, a group of compounds known for their
anxiolytic and antiepileptic properties (So´lyom and Tarnawa,
2002). GYKI 52466 and structurally-related members that are
AMPA/kainate receptor antagonists are currently undergoing
clinical trials. For example, Talampanel (GYKI 53773, alterna-
tively named LY300164), a synthetic derivative of dioxolobenzo-
diazepine, is currently being evaluated for efficacy at reducing
symptoms of a variety of neurological conditions such as Parkin-
son’s (clinical trial identifiers: NCT00108667, AMPA Receptor
Antagonist Treatment of Parkinson’s Disease; NCT00036296,
Effects of Talampanel on Patients With Advanced Parkinson’s
Disease Who Have Been on Sinemet for More Than 5 Years
and Have Dyskinesia; NCT00696332, A Multinational, Multi-
center, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Study to Assess the Efficacy, Tolerability and
Safety of Talampanel in Subjects With Amyotrophic Lateral Scle-
rosis (ALS); NCT00034814, Efficacy and Safety of Talampanel as
Adjunctive Therapy in Patients With Partial Seizures: A Phase II
Clinical Trial). Additionally, perampanel (E2007), a 1,5-
substituted bipyridinylone, is a first-in-class, orally administered,
and highly selective noncompetitive AMPAR antagonist
currently undergoing trials for several neurological indications
(clinical trial Identifiers: NCT00505622, A Multi-Centre, Open
Label Extension Study to Evaluate the Long-Term Safety,
Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive
Therapy in Levodopa Treated Parkinson’s Disease Subjects
With Motor Fluctuations; NCT00592774, A Multicenter,
Randomized, Double-Blind, Placebo-Controlled, Dose-Tolera-
bility Titration Study To Evaluate The Efficacy And Safety Of Per-
ampanel (E2007) In Patients With Post-Herpetic NeuralgiaNeuron 67, July 15, 2010 ª2010 Elsevier Inc. 17
Table 1. Past and Ongoing Clinical Trials with Selective AMPAR Antagonists
Talampanel
Status Study Condition Intervention
Terminated absorption, metabolism
and excretion of talampanel
healthy drug: talampanel (non-
radiolabeled), [14C] talampanel
Not yet
recruiting
effects of talampanel
on the heart rhythm (phase 1)
healthy drug: talampanel; drug:
moxifloxacin; drug: placebo
Active, not
recruiting
talampanel for amyotrophic lateral sclerosis
(ALS)
ALS drug: talampanel; drug: placebo
Completed multicenter trial for adults
with partial seizures
epilepsy drug: talampanel; drug: placebo
Active, not
recruiting
talampanel in treating patients
with recurrent high-grade glioma
brain and central
nervous system tumors
drug: talampanel
Active, not
recruiting
safety and efficacy of talampanel
in glioblastoma multiforme
glioblastoma multiforme drug: Talampanel
Completed effects of talampanel on patients
with advanced parkinson’s disease
dyskinesias; Parkinson’s
disease; movement disorders
drug: talampanel
Terminated talampanel in patients with recurrent high
grade gliomas (phase 2)
glioblastoma multiforme; anaplastic
astrocytoma; anaplastic
oligodendroglioma; anaplastic
mixed oligoastrocytoma
drug: talampanel
Completed talampanel to treat Parkinson’s disease Parkinson’s disease drug: IV levodopa; drug: talampanel
Completed effect of talampanel (an AMPA
receptor blocker) on brain activity
healthy drug: talampanel
Tezampanel
Completed safety, tolerance and efficacy of
tezampanel in patients with acute migraine
migraine drug: tezampanel
Perampanel
Recruiting efficacy and safety of E2007 (perampanel)
given as adjunctive therapy in subjects with
refractory partial seizures
refractory partial seizures drug: E2007 (perampanel); drug:
placebo
Recruiting efficacy and Safety of E2007 (Perampanel)
given as adjunctive therapy in subjects with
refractory partial seizures
refractory partial seizures drug: E2007 (perampanel); drug:
placebo
Completed dose-tolerability titration study to evaluate
the efficacy and safety of perampanel
(E2007) in patients with post-herpetic
neuralgia (PHN)
neuralgia drug: E2007 (perampanel); drug:
placebo
Recruiting efficacy and safety of E2007 (perampanel)
given as adjunctive therapy in subjects with
refractory partial seizures
refractory partial seizures drug: perampanel; drug: placebo
Recruiting efficacy and safety of E2007 (perampanel)
given as adjunctive therapy in subjects with
refractory partial seizures
epilepsy drug: perampanel; drug: placebo
Terminated long-term safety, tolerability, and efficacy of
perampanel (E2007) as an adjunctive
therapy in levodopa treated parkinson’s
disease subjects with motor fluctuations
Parkinson’s disease drug: perampanel
Active, not
recruiting
E2007 (perampanel) in patients with painful
diabetic neuropathy (PDN) or post-herpetic
neuralgia (PHN)
neuralgia drug: E2007
Completed efficacy and safety of E2007 in patients with
painful diabetic neuropathy
diabetic neuropathy drug: placebo; drug: E2007 (2 mg);
drug: E2007 (4 mg); drug: E2007 (6
mg); drug: E2007 (8 mg)
Active, not
recruiting
four-year open-label extension phase of the
parallel-group study of E2007 in patients
with refractory partial seizures
refractory partial seizures drug: E2007 (perampanel)
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Table 1. Continued
Talampanel
Terminated assessment of perampanel (E2007) on
synaptic dopamine in mild-moderate PD
patients: a pilot study with [^123I]-IBZM
SPECT
Parkinson’s disease drug: E2007
Recruiting a long-term extension study of E2007 in
patients with refractory partial seizures
uncontrolled with other anti-epileptic drugs
(AEDs)
refractory partial seizures drug: perampanel
Neuron
Review(PHN); NCT00700310, A Double-Blind, Placebo-Controlled,
Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy
and Safety of E2007 (Perampanel) Given as Adjunctive Therapy
in Subjects With Refractory Partial Seizures; NCT00699582,
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-
Group Study to Evaluate the Efficacy and Safety of E2007
(Perampanel) Given as Adjunctive Therapy in Subjects With
Refractory Partial Seizures; NCT00699972, A Double-Blind,
Placebo-Controlled, Dose-Escalation, Parallel-Group Study to
Evaluate the Efficacy and Safety of E2007 (Perampanel) Given
as Adjunctive Therapy in Subjects With Refractory Partial
Seizures; NCT00592904, A Multi-Center, Open-Label Extension
Study to Evaluate the Long-Term Safety, Tolerability, and Effi-
cacy of E2007 (Perampanel) in Patients With Painful Diabetic
Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)).
Perhaps the most promising compound from the decahydroi-
soquinoline family of AMPA/kainate receptor antagonists is te-
zampanel (NGX424), which has recently been used in a
double-blind, placebo controlled, parallel group, multicenter
phase 1 study (clinical trial identifier: NCT00567086, A Double-
Blind, Placebo-Controlled, Parallel Group Multicenter Study to
Assess the Safety, Tolerance and Efficacy of a Single Subcuta-
neous Dose of TEZAMPANEL in Patients With Acute Migraine).
Importantly, the ester prodrug of tezampanel (NGX426) is
bioavailable after oral administration and has also successfully
completed phase 1 clinical trials (clinical trial identifier:
NCT00832546, A Double-Blind, Randomized, Placebo Con-
trolled, Cross-Over, Safety Tolerance and Experimental
Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers).
The AMPAR antagonists evaluated in clinical trials appear to be
generally well tolerated, with only a few subjects reporting minor
side effects such as dry mouth, dizziness and sedation (Gottwald
and Aminoff, 2008; Pascuzzi et al., 2010). These early human
trials are particularly interesting given that tezampanel reduced
rat cocaine self-administration (Di Ciano and Everitt, 2001).
Clinical Trials with Nonspecific AMPAR Antagonists
Encouraging results have also been generated with agents that
exhibit less specificity of action. Topiramate is commonly used
as monotherapy in patients with partial onset or primary general-
ized tonic-clonic seizures and is FDA approved for migraine
prevention. In addition to AMPAR antagonism, topiramate also
enhances GABA levels in the CNS (Kuzniecky et al., 1998; Petroff
et al., 1999; White et al., 2007). Interestingly, a double-blind,
placebo-controlled pilot trial showed that topiramate-treated
subjects were more likely to remain abstinent from cocaine use
(Kampman et al., 2004) as craving intensity and duration werereduced in 25% of patients tested. Intriguingly, acute topiramate
enhanced the pleasant subjective effects of methamphetamine
(Johnson et al., 2007), suggesting a potential for replacement
therapy. However, topiramate did not alter the rewarding proper-
ties of methamphetamine in mice (Tatsuta et al., 2007).
A randomized, double-blind, placebo-controlled topiramate trial
for alcohol and cocaine dependence is underway (clinical trial
identifier: NCT00167245, A Phase II, Randomized, Double-blind,
Placebo-Controlled, Pilot Trial of Topiramate for Alcohol and Co-
morbid Cocaine Dependence; NCT00223626, Lab Trials to
Develop Medication for Cocaine Dependence). The anticonvul-
sant and mood stabilizer drug lamotrigine also exhibits antago-
nistic effects on AMPAR and reduces glutamate release (Lee
et al., 2008). Importantly, two open-label studies have correlated
lamotrigine with significant reductions in cocaine craving and
use (Brown et al., 2003). Additional studies are recruiting patients
at the time that this review was prepared (clinical trial identifier:
NCT00280293, A Randomized, Double-Blind, Placebo-
Controlled, Trial of Lamotrigine Add-on Therapy in Outpatients
With Bipolar Disorder, Depressed or Mixed Phase and Cocaine
Dependence).
Glutamatergic Modulators
A variety of agents that modulate glutamate receptor activity are
also being studied as potential treatments against substance
abuse. Reagents that increase basal extracellular levels of gluta-
mate are also effective at preventing relapse and several forms of
cocaine-induced plasticity (Baker et al., 2003; Knackstedt et al.,
2010; Madayag et al., 2007; Martı´nez-Raga et al., 2008; Moran
et al., 2005). Increased basal glutamate is thought to act on
generally high-affinity autoreceptors to reduce the cue-, drug-,
or stress-primed glutamate that acts through AMPAR to drive
relapse (Baker et al., 2003). Accordingly, activation of receptors
that can act as glutamate autoreceptors reduce cocaine seeking
(Adewale et al., 2006; Peng et al., 2010; Peters and Kalivas,
2006; but see Bauzo et al., 2009). Thus, it is plausible to hypoth-
esize a scenario where inhibiting excessive AMPA signaling
while also promoting the diminished basal glutamatergic
signaling that is often observed following repeated exposure to
cocaine would represent a very effective way to prevent relapse.
Indeed, other agents that weakly elevate activity of other gluta-
mate receptors such as NMDARs, have shown some efficacy
to reduce cocaine reinforcement in preclinical models (Bowers
et al., 2007). Phase I clinical trials with campral (acamprosate),
a nonspecific glutamate receptor modulator, have been
completed (clinical trial identifier: NCT00385268, Pilot Trial of
Acamprosate for the Treatment of Cocaine Dependence).Neuron 67, July 15, 2010 ª2010 Elsevier Inc. 19
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sate might also block the AMPA receptor pore, given the ability
to modulate polyamine binding to the NMDA receptor
(Kast and Altschuler, 2007). Similarly, agents such as provigil
(modafinil), mucomyst/acetadote (N-acetyl cysteine), and roce-
phin (ceftriaxone) have shown efficacy to reduce cocaine
seeking (Baker et al., 2003; Knackstedt et al., 2010; Madayag
et al., 2007; Martı´nez-Raga et al., 2008; Moran et al., 2005).
N-acetylcysteine elevates glutamate levels affecting both
ionotropic and metabotropic glutamate receptors and is
currently being studied as a therapeutic agent against substance
abuse (clinical trial identifiers: NCT00136825, Effectiveness of
N-Acetylcysteine in Treating Cocaine Dependent Individuals;
NCT00218491, Effectiveness of N-Acetylcysteine (NAC) in
Treating Cocaine Dependent Individuals). A thorough discussion
of these compounds is beyond the scope of this review, but
recent reviews have discussed the therapeutic potential of the
most promising agents (Uys and LaLumiere, 2008; Kalivas,
2009).
Conclusions
While few, clinical studies performed with either selective or
nonselective AMPAR antagonists suggest the therapeutic
potential of this reagent class. Additional placebo-controlled,
double-blind studies are needed to properly evaluate the clinical
utility of these and similar compounds for substance abuse.
Moreover, drugs acting nonspecifically at AMPARs should be
further evaluated for efficacy to reduce cocaine seeking. At
present, our armamentarium of clinically useful AMPAR antago-
nists is very limited; therefore, the development of novel AMPAR
antagonists with fewer side effects is needed.
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